Cellyan Biotechnology Co., Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report, dated March 26, 2026, covers a private placement transaction executed by Cellyan Biotechnology Co., Ltd., a Cayman Islands exempted company. The report details the issuance of securities to raise capital for business expansion, working capital, and general corporate purposes.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6,500,000.
- Securities Issued: 12,499,986 Units.
- Unit Composition: Each Unit consists of one Class A Ordinary Share and two Warrants.
- Purchase Price: $0.52 per Unit.
- Warrant Terms: Three-year term with an exercise price of $0.01 per share.
- Closing Date: March 25, 2026.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels as this report focuses solely on the capital raise event.
Material Changes and Transaction Structure
The Company entered into Securities Purchase Agreements on March 24, 2026, with certain Investors. The transaction was conducted as a private placement relying on exemptions under Section 4(a)(2) of the Securities Act of 1933 and Regulation S. Consequently, the securities were not offered to the public, and no general solicitation was used. Investors represented they are not "U.S. persons."
In connection with the placement, the Company signed a Registration Rights Agreement, obligating it to file a registration statement with the SEC within 30 calendar days of the closing date to register the resale of the shares and shares issuable upon warrant exercise.
Guidance, Risks, and Contingencies
Use of Proceeds: Management intends to utilize the funds for business expansion, working capital, and general corporate purposes.
Warrant Restrictions: Holders cannot exercise warrants if doing so would result in beneficial ownership exceeding 4.99% of outstanding shares (increasable to 9.99% at the holder's election). Warrants allow for cashless exercise if no effective registration statement is in place at the time of exercise.
Risk Factors: The filing includes a cautionary note regarding forward-looking statements, noting that actual results may differ due to competitive environments and emerging risks. The unregistered shares are subject to transfer restrictions and cannot be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the filing of the initial registration statement within 30 days of the March 25, 2026 closing date as required by the Registration Rights Agreement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant form (Exhibit 4.1) for specific covenants and conditions.
- Confirm the identity of the Investors and their compliance with Regulation S requirements.
- Monitor the Company's subsequent filings for updates on the deployment of the $6.5 million in proceeds.